Successful treatment of schizophrenia with melperone augmentation in a patient with phenotypic CYP2D6 ultrarapid metabolization: a case report
1 Department of Psychiatry and Psychotherapy III, University of Ulm, Ulm, Germany
2 Department of Neurology, University of Ulm, Ulm, Germany
Journal of Medical Case Reports 2012, 6:49 doi:10.1186/1752-1947-6-49Published: 6 February 2012
There are limited treatment options for people with schizophrenia with cytochrome P450 2D6 ultrarapid metabolizer status who do not respond to amisulpride.
Furthermore, the literature does not provide evidence-based guidelines for this particular constellation.
We report the case of a 50-year-old Caucasian female patient with schizophrenia and cytochrome P450 2D6 ultrarapid metabolizer status who experienced an insufficient antipsychotic effect with amisulpride. She was successfully treated with melperone-augmented haloperidol.
This report yields melperone-augmented haloperidol as a possible pharmacological strategy in the described situation. In addition, our observations support the available evidence for the potential of melperone to act as an inhibitor of cytochrome P450 2D6.